Target: DLL3 (Delta-like protein 3)

Indication: Small Cell Lung Cancer (SCLC)

1. Surface Eligibility (hard requirement)

Localization (UniProt evidence):
- Subcellular localizations: Golgi apparatus, Cell membrane
- Topology: Single-pass type I membrane protein
- Transmembrane domains: 1
- Note: Predominantly Golgi/intracellular; low cell-surface density limits ADC but works for T-cell engager (tarlatamab).

Interpretation

DLL3 is a single-pass type I membrane protein, which structurally implies:
- An extracellular N-terminal domain
- A single transmembrane helix
- A cytoplasmic C-terminal tail

Thus, DLL3 is formally surface-eligible, because it possesses an extracellular domain.

However, UniProt notes that it is predominantly Golgi/intracellular, with low cell-surface density. This is a critical nuance:
- CAR-T / TCE (high sensitivity, serial killing) → more tolerant of low density
- ADCs → may be more limited by low antigen density

✅ Conclusion: Surface eligible, but surface density may be limiting depending on modality.

2. On-Tumor Signal (TCGA SCLC)

Tumor median TPM:

• SCLC: 60.0 TPM

Comparator cohorts:
- LUAD: 2.0
- LUSC: 2.0
- GBM: 8.0
- Most others: 0.5–3.0

Interpretation

DLL3 expression in SCLC (60 TPM) is:
- ~30× higher than LUAD/LUSC (2 TPM)
- ~60× higher than many epithelial tumors (1 TPM)
- Substantially higher than GBM (8 TPM)

This is a very strong, lineage-restricted tumor signal within the TCGA dataset.

✅ Excellent on-tumor signal for SCLC

3. Tumor vs Normal Specificity (Dominant Criterion)

Normal tissue median TPM (selected key tissues):

• Brain – Cortex: 2.0
• Pancreas: 1.0
• Testis: 1.0
• Nerve – Tibial: 0.5
• Lung: 0.3
• Heart – Left Ventricle: 0.1
• Liver: 0.1
• Kidney – Cortex: 0.1
• Colon – Transverse: 0.1
• Whole Blood: 0.1
• Spleen: 0.1

Tumor (SCLC): 60.0 TPM

Tumor-to-normal ratios:

• vs Brain cortex: 60 / 2.0 = 30×
• vs Pancreas/Testis: 60 / 1.0 = 60×
• vs Lung: 60 / 0.3 = 200×
• vs Heart/Liver/Kidney/Blood: 60 / 0.1 = 600×

Interpretation

• DLL3 shows very strong tumor specificity.
• Absolute expression in vital tissues is low (≤2 TPM).
• Even the highest normal tissue (brain cortex at 2 TPM) is 30-fold lower than SCLC.

Given:
- Brain is a dose-limiting organ
- DLL3 is mostly intracellular in normal tissues
- Absolute TPM is modest

Overall specificity profile is favorable.

✅ Excellent tumor-vs-normal differential

4. Safety Considerations

Vital tissues (selected):

Key observations:
- No high expression in heart, liver, kidney, lung, or blood.
- Brain expression is present (2 TPM), but still low relative to tumor (60 TPM).
- Hematologic tissues are minimal → low risk of marrow aplasia.

Given low normal expression and predominantly intracellular localization in non-tumor contexts, on-target/off-tumor toxicity risk appears manageable, particularly for controlled modalities (e.g., bispecifics).

FINAL ASSESSMENT

Target: DLL3
Indication: Small Cell Lung Cancer (SCLC)

Surface Eligibility

Eligible for cell-surface therapeutics.
Evidence: Single-pass type I membrane protein with cell membrane localization and an extracellular domain. UniProt notes predominant Golgi localization and low surface density, which may limit ADC performance but remains compatible with CAR-T or T-cell engager approaches.

On-Tumor Signal

• SCLC: 60.0 TPM (very high)

Specificity (Tumor vs Normal — dominant criterion)

• Brain cortex: 2.0 TPM
• Pancreas: 1.0 TPM
• Lung: 0.3 TPM
• Heart/Liver/Kidney/Blood: 0.1 TPM
• Tumor-to-normal differential: 30×–600× depending on tissue

This represents a strong and selective tumor expression pattern.

Safety

• Minimal expression in heart, liver, kidney, blood.
• Low-level brain expression (2 TPM) warrants monitoring.
• Overall vital tissue exposure risk appears low-to-moderate but manageable.
• Intracellular predominance in normal tissues may further mitigate toxicity risk.

Tier

✅ Tier 1 – Strong

Rationale and Recommendation

DLL3 demonstrates high SCLC-restricted expression (60 TPM) with low expression across vital normal tissues (≤2 TPM), yielding an excellent tumor-to-normal differential. It is structurally a surface protein with an extracellular domain, satisfying the hard requirement for CAR-T, ADC, and T-cell engager modalities, though its predominantly intracellular localization suggests that modality choice matters (T-cell engagers/CAR-T likely superior to ADC).

Overall, DLL3 is a high-priority tumor-associated antigen for SCLC, with strong specificity and acceptable safety margins. It qualifies as a Tier 1 target for cell-surface immunotherapeutic strategies in SCLC.